Treatment | Dosages (ug/mL) | Amastigote L. major/peritoneal cell | Amastigote L. major/J774 cell-line | ||||||
---|---|---|---|---|---|---|---|---|---|
Time(h) | I% | V% | I % | V% | |||||
72Â h | 120Â h | 72Â h | 120Â h | 72Â h | 120Â h | 72Â h | 120Â h | ||
No-treatment control | 0 | 73.7 ± 3.7 | 68.3 ± 4.1 | 100 ± 0 | 100 ± 0 | 61.3 ± 3.7 | 47 ± 2.9 | 100 ± 0 | 100 ± 0 |
Saliva | 150 | 65.7 ± 5 | 35 ± 3.5 | 71.2 ± 4 | 50.5 ± 4.3 | 51 ± 3.9 | 31 ± 2.1 | 52.8 ± 4.2 | 47.5 ± 3.3 |
450 | 52.7 ± 3.6 | 28 ± 2.8 | 61.5 ± 3.7 | 44.2 ± 3.1 | 41 ± 1.8 | 23.3 ± 2.5 | 42.7 ± 1.4 | 37.3 ± 3.7 | |
Hemolymph | 150 | 59 ± 2.5 | 22.7 ± 1.8 | 65.7 ± 4.2 | 43.6 ± 2.9 | 47 ± 4.7 | 26.3 ± 3.6 | 41.4 ± 3.5 | 34.3 ± 4 |
450 | 41.7 ± 3.7 | 16.3 ± 4.4 | 43.7 ± 3.3 | 30.5 ± 1.8 | 29.3 ± 321 | 10 ± 1.1 | 31.7 ± 2.8 | 14.8 ± 2.7 | |
Positive control Glucantime | 50 | 51 ± 2.3 | 29.3 ± 3.8 | 59.2 ± 3.7 | 41 ± 1.8 | 43.8 ± 1.8 | 22 ± 1.5 | 51.7 ± 2.5 | 43.5 ± 1.4 |
100 | 38.3 ± 3.1 | 14 ± 2.16 | 46.2 ± 2.7 | 29 ± 2.8 | 31.7 ± 2.6 | 12.5 ± 1.2 | 37.1 ± 4 | 16.7 ± 1.8 |